A COMPARISON OF LUCERNE VARIETIES IN SOUTH-WEST SCOTLAND

Five early, three mid-season and two late varieties of lucerne were grown in drills in a replicated plot experiment at the Hannah Dairy Research Institute in south-west Scotland in the period 1956–59, inclusive. The lucerne was cut three times each year after the year of establishment (1956).
Average yields were 10,200 lb. of dry matter and 1970 lb. of crude protein per acre in the first harvest year, but declined rapidly to 6290 lb. of dry matter and 1190 lb. of crude protein per acre in the third year. On average, the early types of lucerne gave the highest yields of dry matter and crude protein. Over the three harvest years of the experiment, Flandria was the highest yielding variety and New Zealand B the lowest. The distribution of dry-matter yields averaged over all varieties was 44, 29 and 27% for cuts 1, 2 and 3, respectively.
The crude-protein content of the herbage from all the varieties was high, 63% of the values being greater than 19%. Grimm, a late variety, had the highest crude-protein content.
With all varieties tiller density declined rapidly from the first to the second harvest year, but increased again at the third harvest year.
11–34% of the total yield of dry matter in the second harvest year consisted of weed grasses, but this was reduced in the following year by spraying the plots with Dowpon, a selective herbicide.     

Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIα activity through ATP-competitive inhibition

Type IIα DNA topoisomerase (TopoIIα) is among the most important clinical drug targets for the treatment of cancer. Recently, the DNA repair protein Metnase was shown to enhance TopoIIα activity and increase resistance to TopoIIα poisons. Using in vitro DNA decatenation assays we show that neoamphimedine potently inhibits TopoIIα-dependent DNA decatenation in the presence of Metnase. Cell proliferation assays demonstrate that neoamphimedine can inhibit Metnase-enhanced cell growth with an IC(50) of 0.5 μM. Additionally, we find that the apparent K(m) of TopoIIα for ATP increases linearly with higher concentrations of neoamphimedine, indicating ATP-competitive inhibition, which is substantiated by molecular modeling. These findings support the continued development of neoamphimedine as an anticancer agent, particularly in solid tumors that over-express Metnase.     

Interactions between glyphosate and imazethapyr on four annual weeds

Greenhouse and field experiments were conducted to evaluate the efficacy of various combinations of imazethapyr (0, 23, 46, and 70 g ai/ha) with glyphosate (0, 210, 420, 630, and 840 g ae/ha) on Setaria faberi, Amaranthus rudis, Abutilon theophrasti, and Ipomoea hederacea control. Additivity was the most frequently observed interaction and no synergistic interaction occurred throughout this study. The combination of imazethapyr with glyphosate at 210 g/ha caused an antagonistic response on Setaria faberi. Glyphosate at 420 g/ha with or without imazethapyr provided at least 95% control of Setaria faberi. The interaction between glyphosate and imazethapyr was additive on Amaranthus rudis control. Eight of the twenty-one herbicide combinations were antagonistic on Abutilon theophrasti control. Antagonistic interactions occurred when 46 or 70 g/ha of imazethapyr was added to 420 or 630 g/ha of glyphosate; while no antagonistic interactions were noted when glyphosate rate was 840 g/ha. The interactions on Ipomoea hederacea control were additive when the glyphosate rate was at least 420 g/ha. Glyphosate at 210 g/ha plus imazethapyr at 46 or 70 g/ha caused antagonistic interactions on Ipomoea hederacea control. Weed control tended to be more variable when the glyphosate rate was 210 g/ha and the imazethapyr rate was 46 or 70 g/ha. In general, the addition of imazethapyr to low rates of glyphosate improved control of Amaranthus rudis and Ipomoea hederacea and did not improve control of Setaria faberi and Abutilon theophrasti.     

Association analysis reveals effects of wheat glutenin alleles and rye translocations on dough-mixing properties

The glutenin loci of wheat (Triticum aestivum L.) are important determinants of bread-making quality, although the effects of alleles at those loci are incompletely understood. We applied an association analysis method to assess the effects of glutenin alleles and 1RS wheat–rye (Secale cereale L.) translocations on dough-mixing properties in 96 wheat cultivars and advanced lines grown at three Colorado locations while accounting for population structure and relatedness of individuals in the population. The results indicated that (1) in the majority of cases, controlling relatedness of individuals reduced the significance of associations between glutenin loci and Mixograph traits; (2) the Glu-D1 and Glu-B3 loci and 1RS translocations had greater impacts on dough-mixing properties compared to other glutenin loci; (3) Glu-B1w, Glu-D1d, and Glu-B3b were consistently associated with greater (more favorable) Mixograph peak time (MPT) than other alleles at the respective loci, whereas Glu-B1e, Glu-D1a, and Glu-B3c were associated with reduced MPT; (4) the 1BL.1RS translocation was associated with a decrease in Mixograph properties. Our results indicate that taking multiple-level relatedness of individuals into account can improve the results of association analysis for wheat-quality traits.     

Comparison of Methods for Gluten Strength Assessment

Five methods that employed very different testing principles and procedures for assessing gluten quality were compared for 33 North American soft red and white wheats. The three methods analyzed flour (alveograph work, lactic acid solvent retention capacity, and mixograph peak time) and two methods employed ground wheat meal (Glutomatic gluten index and SDS sedimentation volume). Compared against the normalized mean of all five assessments, the ability of the assessment methods to evaluate gluten quality decreased in the order: alveograph work, lactic acid solvent retention capacity, mixograph peak time, Glutomatic gluten index, and SDS sedimentation volume. The methods utilizing flour were substantially superior predictive methods; however, the two meal‐based methods could be sufficient for early generation screening when flour is not available.     

Pharmacokinetics and pharmacodynamics of enrofloxacin and a low dose of amikacin administered via regional intravenous limb perfusion in standing horses

OBJECTIVE: To evaluate the pharmacokinetic-pharmacodynamic parameters of enrofloxacin and a low dose of amikacin administered via regional IV limb perfusion (RILP) in standing horses. ANIMALS: 14 adult horses. PROCEDURES: Standing horses (7 horses/group) received either enrofloxacin (1.5 mg/kg) or amikacin (250 mg) via RILP (involving tourniquet application) in 1 forelimb. Samples of interstitial fluid (collected via implanted capillary ultrafiltration devices) from the bone marrow (BMIF) of the third metacarpal bone and overlying subcutaneous tissues (STIF), blood, and synovial fluid of the radiocarpal joint were collected prior to (time 0) and at intervals after tourniquet release for determination of drug concentrations. For pharmacokinetic-pharmacodynamic analyses, minimum inhibitory concentrations (MICs) of 16 microg/mL (amikacin) and 0.5 microg/mL (enrofloxacin) were applied. RESULTS: After RILP with enrofloxacin, 3 horses developed vasculitis. The highest synovial fluid concentrations of enrofloxacin and amikacin were detected at time 0; median values (range) were 13.22 microg/mL (0.254 to 167.9 microg/mL) and 26.2 microg/mL (5.78 to 50.0 microg/mL), respectively. Enrofloxacin concentrations exceeded MIC for approximately 24 hours in STIF and synovial fluid and for 36 hours in BMIF. After perfusion of amikacin, concentrations greater than the MIC were not detected in any samples. Effective therapeutic concentrations of enrofloxacin were attained in all samples. CONCLUSIONS AND CLINICAL RELEVANCE: In horses with orthopedic infections, RILP of enrofloxacin (1.5 mg/kg) should be considered as a treatment option. However, care must be taken during administration. A dose of amikacin > 250 mg is recommended to attain effective tissue concentrations via RILP in standing horses.     

Preserving new anthelmintics: a simple method for estimating faecal egg count reduction test (FECRT) confidence limits when efficacy and/or nematode aggregation is high

As it has been 30 years since a new anthelmintic class was released, it is appropriate to review management practices aimed at slowing the development of anthelmintic resistance to all drug classes. Recommendations to delay anthelmintic resistance, provide refugia and the use of a simulation model were reviewed to find optimum treatment strategies that maintain nematode control. Simulated Australian conditions indicated that a common successful low-risk treatment program was a rapid rotation between a "triple-combination" product (benzimidazole+levamisole+abamectin) and a new high-efficacy drug (monepantel). Where Haemonchus contortus was a threat, moxidectin was required at critical times because of its persistent activity against this parasite. Leaving up to 4% of adult sheep untreated provided sufficient "refugia" for non-selected worms to reduce the risk of selecting for anthelmintic resistance without compromising nematode control. For a new anthelmintic, efficacy estimated by faecal egg count reduction (FECR) is likely to be at or close to 100%, however using current methods the 95% confidence limits (CL) for 100% are incorrectly determined as 100%. The fewer eggs counted pre-treatment, the more likely an estimate of 100% will occur, particularly if the true efficacy is >90%. A novel way to determine the lower-CL (LCL) for 100% efficacy is to reframe FECR as a binomial proportion, i.e. define: n and x as the total number of eggs counted (rather than eggs per gram of faeces) for all pre-treatment and post-treatment animals, respectively; p the proportion of resistant eggs is p = x/n and percent efficacy is 100 ×(1-p) (assuming equal treatment group sizes and detection levels, pre- and post-treatment). The LCL is approximated from the cumulative inverse beta distribution by: 95%LCL=100 ×(1-(BETAINV(0.975, x+1, n-x+1))). This method is simpler than the current method, independent of the number of animals tested, and demonstrates that for 100% efficacy at least 37 eggs (not eggs per gram) need to be counted pre-treatment before the LCL can exceed 90%. When nematode aggregation is high, this method can be usefully applied to efficacy estimates lower than 100%, and in this case the 95% upper-CL (UCL) can be estimated by: 95% UCL = 100 ×(1((BETAINV(0.025, x+1, n-x+1))), with the LCL approximated as described above. A simulation study to estimate the precision and accuracy of this method found that the more conservative 99%CL was optimum; in this case 0.975 and 0.025 are replaced by 0.995 and 0.005 to estimate the LCL and UCL, respectively.